奥佐利珠单抗：首次获批。
Ozoralizumab: First Approval.
作者信息
Keam Susan J
机构信息
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
出版信息
Drugs. 2023 Jan;83(1):87-92. doi: 10.1007/s40265-022-01821-0.
Ozoralizumab (Nanozora), a trivalent anti-tumour necrosis factor alpha (TNFα) NANOBODY compound, has been developed by Taisho Pharmaceutical Co. Ltd (under license from Ablynx, an affiliate of Sanofi) for the treatment of rheumatoid arthritis (RA). In September 2022, ozoralizumab was approved in Japan for the treatment of RA that is inadequately managed by current available treatments. This article summarizes the milestones in the development of ozoralizumab leading to this first approval.
奥佐利珠单抗（Nanozora）是一种三价抗肿瘤坏死因子α（TNFα）纳米抗体化合物，由大正制药株式会社（根据赛诺菲旗下子公司Ablynx的许可）开发，用于治疗类风湿性关节炎（RA）。2022年9月，奥佐利珠单抗在日本获批，用于治疗现有治疗方法控制不佳的RA。本文总结了奥佐利珠单抗研发过程中促成这一首次获批的各个重要阶段。
Zotero 插件